ClinicalTrials.gg
RecruitingNCT07059494Updated Jul 28, 2026

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

A Phase 4 interventional study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 4, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing atezolizumab in Carcinoma, Hepatocellular — 17 open to participants now, 29 under way, 7 of them phase 3. atezolizumab · Carcinoma, Hepatocellular.

Planned enrollment
20th of 41
40 · median 40
Started
2026
with 5 others
Phase 4
2 of 41
2 open now
Primary completion
2027-08
later than 18 of 28 live
Registered
35th of 41
by date

Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, this one is the 20th largest by planned enrollment, is one of 6 that started in 2026, is one of 2 in phase 4, reaches primary completion later than 18 of the 28 other live ones, and was the 35th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 41 studies testing atezolizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing atezolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

A single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y\^90 therapy with systemic atezolizumab and bevacizumab, in participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC) with AFP ≥ 400 ng/ml as a means of bridge therapy prior to transplant, 2) beyond the Milan Criteria (MC) (within USCF DS criteria and all comers), as a means of downstaging prior to liver transplantation.

Read the detailed description

The researchers propose a single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y\^90 therapy with systemic atezolizumab and bevacizumab, in participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC) with AFP ≥ 400 ng/ml as a means of bridge therapy prior to transplant, 2) beyond the Milan Criteria (MC) (within USCF DS criteria and all comers), as a means of downstaging prior to liver transplantation. Participants with macrovascular invasion and extrahepatic disease at diagnosis will be excluded from the study. Participants with AFP > 1000 ng/ml at diagnosis will be excluded.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form
  • Age ≥18 years at time of signing Informed Consent Form
  • Ability to comply with the study protocol
  • Newly diagnosed, -proven hepatocellular carcinoma (HCC) that is or cytologically confirmed
  • Availability of a representative tumor specimen that is suitable for determination of status via central testing. A formalin-fixed paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 10-15 slides (15 slides preferred) slides containing unstained, freshly cut, serial sections should be submitted along with an associated pathology report prior to study enrollment. If archival tumor tissue is unavailable or is determined to be unsuitable for required testing, tumor tissue must be obtained from a biopsy performed at screening. Availability of a representative tumor specimen for exploratory biomarker research. Newly diagnosed, biopsy-proven hepatocellular carcinoma (HCC) either outside of the Milan Criteria (MC), or within the MC, with high risk disease as defined by alpha-fetoprotein (AFP) ≥400 ng/mL, and also fulfilling the criteria below.

    1. Within MC with AFP ≥ 400 ng/ml

      1. single lesion (≤5cm) or 3 lesions (≤3cm)
      2. Absence of vascular invasion or extra-hepatic disease based on cross-sectional imaging
      3. Score of A/B7 (without ascites)
    2. UNOS-DS Protocol

      1. HCC exceeding UNOS T2 criteria but meeting one of the following:

        • Single lesion ≤ 8 cm
        • 2 or 3 lesions each ≤ 5 cm with the sum of the maximal tumor diameters ≤8 cm
        • or 5 lesions each ≤ 3 cm with the sum of the maximal tumor diameters ≤ 8 cm
      2. Absence of vascular invasion or extra-hepatic disease based on cross-sectional imaging
      3. Child-Pugh Score of A/B7 (without ascites)
    3. Beyond UNOS-DS Liver Only Protocol a. HCC exceeding UNOS-DS criteria by any of the following:

      • HCC tumor number
      • HCC tumor size
      • Total HCC tumor diameter b. Absence of vascular invasion or extra-hepatic disease based on cross-sectional imaging c. Child-Pugh Score of A/B7 (without ascites)
  • , or non-measurable but evaluable disease, per v1.1 criteria
  • Must meet institutional standards for proteinuria (Urinalysis (pH, specific gravity, glucose, protein, ketones, and blood); dipstick permitted
  • Eligible for treatment with Y\^90 and atezolizumab plus bevacizumab
  • performance status of 0-1
  • > 6 months
  • Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:

    • 1.5 ≥ 10\^9/L (1500/µL) without granulocyte colony-stimulating factor support, with the following exception:
    • Participants with benign ethnic neutropenia (BEN): ANC \< 1.3 x 10\^9/L (1300/μL) BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups.

      • Lymphocyte count ≥ 0.5 x 10\^9/L (500/µL)
      • count ≥ 100 x 10\^9/L (100,000/µL) without transfusion
      • ≥ 90 g/L (9 g/dL)
    • Participants may be transfused to meet this criterion.

      • , ALT, and alkaline phosphatase (ALP) ≤ 2.5 (ULN)
      • Serum ≤ 1.5 x ULN with the following exception:
    • Participants with known Gilbert disease: serum bilirubin ≤ 3 x ULN

      • Serum creatinine ≤ 1.5 x ULN
      • Serum albumin ≥ 25 g/L (2.5 g/dL)
      • For participants not receiving therapeutic anticoagulation: or aPTT ≤ 1.5 x ULN
      • For participants receiving therapeutic anticoagulation: stable anticoagulant regimen
  • Absent or controlled , , and o Participants with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a ≥ 200/μL, and have an undetectable viral load
  • Negative serum pregnancy test within 14 days prior to the initiation of study treatment for participants of .
  • Since adequate studies have not been performed in animals to determine whether Y\^90 affects fertility in males or females has teratogenic potential or has other adverse effects on the fetus, this product should not be administered to pregnant or nursing women unless it is considered that the benefits to be gained outweigh the potential hazards. Ideally the use of this radioactive device in women of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.
  • Agreement to remain abstinent (refrain from heterosexual intercourse) or use methods

Exclusion criteria

Exclusion Criteria:

  • AFP ≥ 1000 ng/ml
  • Pathologically mixed tumors, vascular invasion or extra-hepatic disease based on cross-sectional imaging
  • History of
  • Uncontrolled tumor-related pain

    o Participants requiring pain medication must be on a stable regimen at study entry.

  • Severe pulmonary disease, uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) o Participants with indwelling catheters (e.g., PleurX®) are allowed
  • Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > )
  • Active or history of disease or immune deficiency, including, but not limited to, uncontrolled , myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis (protocol lists a more comprehensive list of autoimmune diseases and immune deficiencies), with the following exceptions:

    • Participants with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
    • Participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    • Participants with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., participants with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

      • Rash must cover \< 10 percent of body surface area
      • Disease is well controlled at baseline and requires only low-potency topical
      • There has been no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan

    o History of radiation pneumonitis in the radiation field (fibrosis) is permitted.

  • Active tuberculosis
  • Significant cardiovascular disease (such as Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 12 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
  • Major surgical procedure, other than for diagnosis or standard HCC care, within 4-6 weeks prior to initiation of study treatment, or during the study
  • Core or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to initiation of study treatment

    o Placement of a vascular access device should be at least 2 days prior to initiation of study treatment

  • History of within 5 years prior to screening, with the exception of malignancies with a negligible risk of or death (e.g., 5-year overall survival (OS) rate > 90 percent), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, bladder cancer, carcinoma in situ, or Stage I uterine cancer
  • Severe active infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, active infection requiring IV antibiotics at the time of initiation of study treatment, or any active infection that could impact participant safety
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment

    o Participants receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or exacerbation) are eligible for the study.

  • Prior allogeneic stem cell, solid organ, or multi-organ transplantation
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including , anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
  • Treatment with systemic medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-α agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:

    • Participants who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.
    • Participants who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Known to Chinese hamster ovary cell products or to any component of the atezolizumab formulation
  • Known allergy or hypersensitivity to any component of the study therapy
  • Prior locoregional or systemic therapy
  • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 6 months after the final dose of study treatment.
  • Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)
  • History of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to randomization
  • History of Grade ≥ 4 venous thromboembolism
  • History or evidence upon physical or neurological examination of central nervous system involvement
  • History of Grade ≥ 2 hemoptysis (defined as ≥ 2.5 mL of bright red blood per episode) within 1 month prior to screening
  • History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)
  • History of abdominal fistula, GI perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization
  • Serious, non-healing wound, active ulcer, or untreated bone fracture
  • Current or recent (\< 10 days prior to initiation of study treatment) use of aspirin (> 325 mg/day), or clopidogrel (> 75 mg/day) Note: The use of full-dose oral or parenteral anticoagulants for therapeutic purpose is permitted as long as the and/or aPTT is within therapeutic limits (according to institution standards) within 7 days prior to initiation of study treatment and the participant has been on a stable dose of anticoagulants for ≥ 2 weeks prior to initiation of study treatment. Prophylactic use of anticoagulants is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) is not recommended due to bleeding risk.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort A: participants beyond Milan Criteria upon enrollment

    Atezolizumab and Bevacizumab in Combination with Y\^90 Radioembolization

    Drug: Atezolizumab · Drug: Bevacizumab · Radiation: Y^90 Radioembolization

  • Experimental
    Cohort B: participants within Milan Criteria with AFP ≥ 400 ng/ml at enrollment.

    Atezolizumab and Bevacizumab in Combination with Y\^90 Radioembolization

    Drug: Atezolizumab · Drug: Bevacizumab · Radiation: Y^90 Radioembolization

Interventions

  • Atezolizumab is an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. It is indicated for usage in Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Hepatocellular Carcinoma (HCC), Melanoma, and Alveolar Soft Part Sarcoma (ASPS).

  • Bevacizumab is a vascular endothelial growth factor inhibitor indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. It is also indicated for the treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in participants who have progressed on a first-line bevacizumab product-containing regimen.

  • RadiationY^90 Radioembolization

    Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat cancers in the liver. Tiny beads filled with a radioactive isotope are placed inside the blood vessels that supply a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue. It can help extend the lives of participants with inoperable tumors and improve their quality of life.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants with Response to treatment

    Cohort A Proportion of participants downstaging to within Milan Criteria as assessed by the rate of radiographic response via CT/MRI pre transplantation (efficacy window of assessment = 9 months from first cycle of Y\^90) Cohort B Response rate to treatment in participants within MC with AFP ≥ 400 ng/ml defined by CT/MRI and a decrease in AFP ≥ 50 percent (efficacy window of assessment = 9 months from first cycle of Y\^90)

    Time frame: 9 months from first cycle of Y^90

Secondary outcomes

  1. Adverse Events

    All pre-transplant AEs and post-transplant related AEs will be summarized based on severity (based on CTCAE v5.0 grade), type of AE, and relationship to study treatment(s). A summary table of AEs will include the number and percentage of participants treated that experienced at least one: AE, SAE, Grade 3 or higher AE, Grade 4 or higher AE, treatment interruption, or dose reduction or treatment discontinuation. Rates of AEs will be calculated as the total number of AEs, SAEs, Grade 3 or higher AE, and Grade 4 or higher AEs per participant cycle on treatment. The analysis will be carried out in the SEAS population.

    Time frame: 1 year

  2. Pathological response

    Rate of pathological response at the time of transplantation (defined as \>70 percent tumor necrosis at explant examination)

    Time frame: At time of transplant procedure

  3. Disease progression

    Disease progression rate beyond baseline MC or post-downstage in participants beyond MC by CT/MRI (Cohort A). Disease progression is defined as per RECIST v1.1 and mRECIST staging criteria.

    Time frame: From time of treatment start to time of disease progression (at 1 year or upon occurrence of event, whichever comes first)

  4. Recurrence-free survival (RFS)

    Assessment of efficacy of Y\^90 in combination with atezolizumab and bevacizumab, pre- and post- transplant as defined Recurrence-free survival (RFS) rate at 1 year post LT, from time of study treatment start to first documented occurrence of intrahepatic or extra hepatic HCC using RECIST v1.1 and mRECIST criteria, or death from any cause, whichever occurs first.

    Time frame: From treatment Day 1 to post-transplant Year 1

  5. Post-transplant recurrence rate

    Assessment of efficacy of Y\^90 in combination with atezolizumab and bevacizumab, pre- and post- transplant as defined by the Post-transplant recurrence rate at 1 year, from day 1 post-transplantation to first documented occurrence of intrahepatic or extra hepatic HCC using RECIST v1.1 and mRECIST criteria, or death, whichever occurs first.

    Time frame: From Day 1 post-transplant to Year 1 post-transplant

  6. Dropout rate from transplant waitlist

    Assessment of efficacy of Y\^90 in combination with atezolizumab and bevacizumab, pre- and post- transplant as defined by the Dropout rate from transplant waitlist

    Time frame: From treatment Day 1 to removal from transplant waiting list (i.e. disease progression, death) up to 3 years

  7. Rate of rejection of liver transplant

    Assessment of efficacy of Y\^90 in combination with atezolizumab and bevacizumab, pre- and post- transplant as defined by the Rate of rejection of liver transplant

    Time frame: From Day 1 post-transplant to Year 1 post-transplant

  8. Duration of response

    The analysis of DOR will be performed on the ITT and PT populations. DOR is defined as time from the first documentation of clinical/radiographical response (per cohort definition of response) that is subsequently confirmed, to death or progression (as determined by the Investigator), whichever comes first. DOR will be censored at the date of last documentation of lack of death or disease progression for patients not known to have died or progressed at the time of data cutoff for analysis. DOR will be calculated only for the subset of patients with a response.

    Time frame: from the first documentation of clinical/radiographical response, until death or progression, (at 1 year or upon occurrence of event) whichever comes first.

  9. Time to the first response

    Time to First response (TFR): Defined as time from the start of treatment to the first documentation of cohort-defined clinical/radiographical response that is subsequently confirmed. TFR will be calculated only for the subset of patients with a confirmed response. In this analysis, clinical/radiographical response (per cohort definition of response) will be the defining event while death without prior progression will be considered the competing event.

    Time frame: Time of start of treatment to first documentation of cohort-defined clinical/radiographical response (at 1 year or upon occurrence of event, whichever comes first)

07

Study locations

1 of 1 sites recruiting
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Parissa Tabrizian · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Clinical study report

Time frame: Immediately following publication. No end date.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. To achieve aims in the approved proposal. Specify Other Mechanism Contact PI Parissa.Tabrizian@mountsinai.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 16 months after the start.

Of 38 phase 4 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jul 10, 2025
StartActual
Mar 26, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2028
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07059494
Collaborators
Genentech, Inc.
Responsible party
Parissa Tabrizian (Associate Professor of Surgery, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jul 10, 2025
Start date
Mar 26, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Jul 28, 2026

Study contacts

Brandy Haydel
Contact
Brandy.Haydel@mountsinai.org
(212) 241-0255
Parissa Tabrizian, MD
principal investigator · Mount Sinai Liver Cancer Program
Josep Llovet, MD, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion